Development of novel anti-osteoporotic drug
Overview
Centre of Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences has constructed in vitro and in vivo models to screen out small molecule drugs for osteoporosis treatment. Further studies were conducted to screen out the protein targets and to perform molecule conformation modification to develop novel drugs.
Technical name of innovation
Novel anti-osteoporosis drug
Research completion
2023
Commercialisation opportunities
Product patent
Problem addressed
By screening and modifying natural small molecules, we tried to develop novel anti-osteoporosis drugs, while lower the side effect of the developed drugs.
Innovation
- By constructing in vitro and in vivo osteoporosis model, we have conducted the screening of the drugs from small molecule library, and characterized the leading chemicals.
- By targeting specefic protein targets, we performed the molecule conformation modification to get the anti-osteoporotic drug with lower side effects.
Key impact
- Based on characterized leading molecule, we tend to perform the conformation modification of the molecules targeting specific protein targets, to develop more effective anti-osteoporotic drugs.
- Lower the cardiovascular risk of current anti-osteoporotic drugs.
- Enhance the life quality of osteoporosis pateints.
Application
- Postmenopausal or other osteoporosis and osteoporotic fracture healing
As the branch organization of the Chinese Academy of Sciences, Hong Kong Institute of Science & Innovation (HKISI) is the first national research institution in Hong Kong SAR approved by the central government of China. Centre for Regenerative Medicine and Health (CRMH), the subsidiary of HKISI, is supported by the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. CRMH is funded by CAS and the InnoHK program from the Innovation and Technology Commission, Hong Kong SAR government. With its focus on stem cell therapy & genomic editing, developmental biology, and drug discovery, CRMH promotes the globalization of regenerative medicine research and achievements.
Enquiry
